Replimune Group, Inc.(REPL)

$15.41—

Chart

Replimune Group, Inc.(REPL)

NASDAQ

$15.41—

Chart Studio

REPL(REPL)

REPL

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

REPL Storieswritten from corroborating sources

Replimune Wins FDA Approval For Melanoma Drug After Two Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval For Melanoma Drug After Two Previous Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval For Melanoma Drug After Two Previous Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval for Melanoma Drug After Two Previous Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval for Melanoma Drug After Two Previous Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval for Melanoma Drug After Two Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval for Melanoma Drug After Two Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval For Melanoma Drug After Two Previous Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval For Melanoma Drug After Two Previous Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval For Melanoma Drug After Two Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval For Melanoma Drug After Two Previous Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago
Replimune Wins FDA Approval for Melanoma Drug After Two Rejections
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Product·2 articles / 2 outlets·18d ago

REPL 0 articles

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance